Kelsey Carter
Primary Care · Orlando, FLNPI 1215539507
Payments from drug & device makers
Across 120 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$408
- GSK$327
- Lilly USA, LLC$275
- AbbVie$250
- Indivior Inc.$214
- Pfizer$208
- plus $932 from 18 others
What the payments were for
- Food & beverage$2,613100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $408 |
| GSK | 15 | $327 |
| Lilly USA, LLC | 17 | $275 |
| AbbVie | 9 | $250 |
| Indivior Inc. | 9 | $214 |
| Pfizer | 13 | $208 |
| Novartis | 5 | $103 |
| Boehringer Ingelheim | 4 | $100 |
| Novo Nordisk | 5 | $96 |
| Amgen | 3 | $88 |
| Insulet Corporation | 3 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $58 |
| Medtronic | 1 | $56 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Verity Pharmaceuticals Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Bayer | 2 | $43 |
| Alkermes, Inc. | 1 | $24 |
| Exact Sciences | 1 | $22 |
| Braeburn Inc. | 1 | $19 |
| Orexo US, Inc. | 1 | $19 |
| Cequr Corporation | 1 | $15 |
| Kerecis Limited | 1 | $10 |
How this compares
$2,613 in reported general payments places this provider in the 85th percentile of 725 primary care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $64,625 |
| Repatha SureclickEvolocumab | 63 | $43,162 |
| MounjaroTirzepatide | 28 | $42,970 |
| JardianceEmpagliflozin | 23 | $25,870 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $15,474 |
| FarxigaDapagliflozin Propanediol | 11 | $13,749 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $13,725 |
| KerendiaFinerenone | 12 | $13,208 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $3,156 |
| Rosuvastatin Calcium | 43 | $1,106 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 19 | $659 |
| Gabapentin | 41 | $545 |
| Bupropion XlBupropion Hcl | 13 | $448 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $428 |
| Atorvastatin Calcium | 46 | $406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $96 | $64,62544 claims |
| Lilly USA, LLCMounjaro | $275 | $42,97028 claims |
| Boehringer IngelheimJardiance | $100 | $25,87023 claims |
| AstraZenecaFarxiga | $408 | $13,74911 claims |
| GSKTrelegy Ellipta | $327 | $13,72513 claims |
| BayerKerendia | $43 | $13,20812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 725 primary care providers in Florida.
Other primary care in Orlando
- Paul ChanOrlando$447K
- Katelyn VignolaOrlando$7K
- Jenny WestPensacola$80K
- Maria Rodriguez ReyesHialeah$31K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.